Neuroscan (Exametazime)

Exametazime, the active ingredient in Neuroscan, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in diagnostic imaging to assess cerebral blood flow, providing clinicians with functional information about brain perfusion in adult patients undergoing evaluation for neurological conditions and aiding treatment planning. The tracer distributes proportionally to regional cerebral blood flow, allowing high‑resolution single‑photon emission computed tomography (SPECT) scans to be generated.

GNH USA supplies Neuroscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neuroscan (exametazime) is used in cerebral perfusion imaging, a diagnostic pathway that evaluates regional blood flow in the brain. - Cerebral perfusion imaging: Provides quantitative assessment of regional cerebral blood flow for diagnostic evaluation. - Brain SPECT: Enables visualization of cerebral perfusion patterns to aid in the diagnosis of stroke, dementia, and epilepsy. - Neurological disorder assessment: Assists in differentiating vascular from neurodegenerative causes by mapping perfusion abnormalities.

Neuroscan may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of injection. - Transient headache: short‑lasting headache occurring shortly after administration. - Nausea: occasional feeling of nausea without vomiting. - Mild flushing: brief skin flushing or warmth.

Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure that may cause dizziness or fainting. - Cardiac arrhythmia: irregular heart rhythm observed in susceptible individuals.

Prior to using Neuroscan, several safety considerations should be observed. - Pregnancy: Use only if clearly needed, as fetal risk is not established. - Breastfeeding: Caution advised; consider temporary cessation of nursing. - Renal impairment: Monitor renal function, as excretion may be altered. - Concurrent radiopharmaceuticals: Avoid overlapping studies that could interfere with image interpretation. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neuroscan can interact with other agents that affect cerebral blood flow or imaging interpretation.

Major Interactions (Avoid): - Other radiopharmaceuticals emitting similar gamma energies: may cause image overlap. - Vasodilators (e.g., nitroglycerin): can significantly alter cerebral perfusion and affect scan accuracy. - High‑dose corticosteroids: may modify regional blood flow patterns.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may modestly reduce cerebral blood flow. - Calcium channel blockers: monitor for potential changes in perfusion. - Sedatives: may affect patient cooperation and motion during SPECT acquisition.